Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.
about
Targeting gastrointestinal stromal tumors: the role of regorafenibThe Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.Current management and prognostic features for gastrointestinal stromal tumor (GIST)HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancerRole of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disordersPhase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumorsPitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors.NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivoA first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.GEIS 2013 guidelines for gastrointestinal sarcomas (GIST)A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.Recent advances and novel agents for gastrointestinal stromal tumor (GIST)Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumors.Imatinib treatment for gastrointestinal stromal tumour (GIST).Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.Imatinib mesylate for the treatment of gastrointestinal stromal tumor.Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies.Targeted therapy in GIST: in silico modeling for prediction of resistance.New molecular targets beyond KIT and PDGFRA in gastrointestinal stromal tumors: present and future.Gastrointestinal stromal tumours--an update for histopathologists.Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.Therapeutic targeting of platelet-derived growth factor receptors in solid tumors.Treatments for gastrointestinal stromal tumors that are resistant to standard therapies.Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance.Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors.The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients.Constitutive activation of oncogenic PDGFRα-mutant proteins occurring in GIST patients induces receptor mislocalisation and alters PDGFRα signalling characteristics.The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842V.The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.In vivo imatinib sensitivity in a patient with GI stromal tumor bearing a PDGFRA deletion DIM842-844.Accomplishments in 2008 in the management of gastrointestinal stromal tumors.Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.New targets and therapies for gastrointestinal stromal tumors.Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07).Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis.
P2860
Q26747162-A2764E26-D0F3-4786-B26B-FCF8883F9C73Q27851619-3B4F11EE-09D9-49FD-9431-FD0C56B6D01EQ27853181-37F3B692-FD32-4CC9-AB89-C16F3564F38CQ28391684-399BC482-EC45-4A88-965F-E181C2345559Q28542855-13A69FE7-27F2-4E7F-8F82-5874508977C7Q28765146-1FF23E50-CAFD-46B2-BCEF-2C4CDEF5E1A0Q29048615-18515C44-3E78-49BA-9AE4-8243052FB5DDQ33621243-2E9201CC-C9C8-417F-AA2D-03627141383BQ33624278-9513EBBF-78C0-4875-8A6D-5EB0726F39C7Q33921067-BC465FE5-A0DF-4BD0-A939-A75E442A6035Q34400894-77FE077C-1D05-49EA-9B62-DF426F90886AQ34636437-4C34DEB7-2680-4710-9771-441894D76B84Q34664305-A0C3221C-C3BA-4F69-B87D-AF24E489F1F9Q35089528-4962BA1A-DF76-4B3F-9032-7040E001A27FQ36118178-224087F6-58E6-413D-9FD8-E4DE03A49AECQ36925163-592D3810-ADC0-41CD-8044-F3469EAAE9A6Q37334993-3B4D2D98-9B72-43FE-90E5-CADAF048A8DDQ37598944-01C3FC67-E84E-4FD7-BBB4-04C2C983DB82Q37752353-26EF63F6-1A7E-446F-AB98-1B4BF0FBA7F9Q37778380-43270216-1896-4CB5-9C85-5444B3847E1BQ37848666-7ACFC14B-336A-4900-A748-37F17A178B0DQ37850810-F3D6AA38-C52E-471B-8BBA-8B6B8C56855CQ37888736-3BE93DDE-A635-4704-96A9-B2AF666FC45DQ37954207-D09BA583-6475-4031-ADD5-35254940354DQ38160946-1D7CFE65-D8D0-447E-89CA-5299F2964371Q38268165-27188195-714D-4EEA-BB75-8D22399D97CAQ38725573-6A59A32F-C805-4FA8-9F25-60B67EC6CE18Q38823874-6D7A603C-4191-497F-9617-9813C8B7D440Q38833685-2F500368-B126-4343-B4F4-2A524555BAA5Q38869809-9E75FA4F-7673-42F0-97C1-558C9D3E7E7CQ38886353-0E2F4AFD-3D4F-42D9-ACD2-25876CFDE053Q39016533-984A12B7-C421-437F-A419-E3D2DDEFC4EFQ39640407-AF5C1C4E-FF5A-4585-A4AD-205BFBA2C8B3Q41819375-C1AF9DE4-2F2F-4098-B4BF-754BAFFE2F9EQ42287336-12DA5BCC-0AC7-467F-B3C7-1455F1A51BE0Q44846748-3D4EAE07-A313-4292-8318-7580B253D9F2Q47432725-B76915E4-D5C9-4EA1-88DA-4C98CC5E1BDAQ48283622-92F7865A-D63E-461A-9158-8EDFF7B4168AQ54113454-BF3F9AF8-75A2-4A0A-9F8C-79CA414DFA36Q54402485-03C67D04-DCCC-4542-A74A-E5D0B259DF60
P2860
Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Activity of dasatinib, a dual ...... sociated PDGFRAD842V mutation.
@en
Activity of dasatinib, a dual ...... sociated PDGFRAD842V mutation.
@nl
type
label
Activity of dasatinib, a dual ...... sociated PDGFRAD842V mutation.
@en
Activity of dasatinib, a dual ...... sociated PDGFRAD842V mutation.
@nl
prefLabel
Activity of dasatinib, a dual ...... sociated PDGFRAD842V mutation.
@en
Activity of dasatinib, a dual ...... sociated PDGFRAD842V mutation.
@nl
P2093
P50
P1476
Activity of dasatinib, a dual ...... ssociated PDGFRAD842V mutation
@en
P2093
Maria Debiec-Rychter
Patrick Schöffski
Peter Marynen
P304
P356
10.1158/1078-0432.CCR-08-0533
P407
P577
2008-09-01T00:00:00Z